Oncotarget

Research Papers:

Stathmin 1 expression predicts prognosis and benefits from adjuvant chemotherapy in patients with gallbladder carcinoma

Xiaobo Bo, Jie Wang, Qiang Fu, Yueqi Wang _, Houbao Liu and Jiejie Xu

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:108548-108555. https://doi.org/10.18632/oncotarget.19625

Metrics: PDF 1185 views  |   HTML 1839 views  |   ?  


Abstract

Xiaobo Bo1,*, Jie Wang1,*, Qiang Fu2, Yueqi Wang1, Houbao Liu1 and Jiejie Xu2

1Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China

*These authors contributed equally to this work

Correspondence to:

Yueqi Wang, email: [email protected]

Houbao Liu, email: [email protected]

Jiejie Xu, email: [email protected]

Keywords: gallbladder carcinoma; stathmin; prognosis; adjuvant chemotherapy; overall survival

Received: April 12, 2017     Accepted: June 30, 2017     Published: July 27, 2017

ABSTRACT

Background: Abnormal expression of Stathmin 1(STMN1) plays an important role in the proliferation and migration of gallbladder carcinoma (GBC). The purpose of current study is to investigate the prognostic significance of STMN1 in GBC patients after surgery.

Methods: STMN1 expression was evaluated with immunohistochemistry (IHC) on tissue microarrays from 70 GBC patients from a single institution between 2009 and 2013. The correlation between STMN1 expression and clinicopathological profiles and the prognosis was statistically inspected.

Results: High expression of STMN1 in tumoral tissue was associated with poor tumor differentiation (P<0.001), lymph node metastasis (P=0.028), advanced TNM stage (P=0.011) and short overall survival (P<0.001). Cox multivariate analysis identified the STMN1 expression as an independent prognostic factor. Integrating STMN1 expression with current TNM staging system generate a better clinical predictive model for GBC. Moreover, the postoperative adjuvant chemotherapy (ACT) showed significant benefit in TNM III- IV stage patients with low STMN1 expression.

Conclusion: STMN1 might be an independent adverse prognostic factor in GBC patients after surgery, which could be combined with TNM staging system to improve the predictive accuracy for overall survival. Low expression of STMN1 stratified a subgroup of advanced GBC patients who could benefit from ACT.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19625